Document:

April 22, 2005

AGU Entertainment Corp.
3200 West Oakland Park Boulevard
Ft. Lauderdale, Florida 33311-1245
Attn: President

Re:   Promissory Note dated December 20, 2004 (the "Note") made payable by AGU
      Entertainment Corp ("Borrower") in favor of Charley Zeches, in her
      capacity as Trustee of Lakes Holding Trust U/A dated July 27, 2001
      ("Lender")

Dear Madam or Sir:

      As of March 20, 2005, a default ("Default") occurred with respect the
payment in the amount of $145,000.00 which was due on March 20, 2005 under the
terms of the Note.

      Lender hereby acknowledges receipt of the amount of $145,000.00 and
accepts the cure of the Default, which acceptance is conditional upon the
issuance of 50,000.00 shares of the Common Stock of AGU Entertainment Corp., to
Elizabeth Buntrock.

      Notwithstanding the foregoing acceptance, this letter shall in no way
obligate Lender in the future to waive any other existing or future default or
Event of Default under the Note or any associated loan documents. Further, this
letter shall not constitute a waiver of any other rights which Lender may have
under the Note or any associated loan documents, instruments or agreements at
any time executed and delivered in connection with the loan by Lender to
Borrower.
                                                    /s/ Elizabeth Buntrock
                                                    -------------------------
                                                    Elizabeth Buntrock
                                                    for Lakes Holding Trust
                                                    22 April 05

cc:     Mitchell Entertainment Company (Via Email)
        Bruce Rosetto, Esq. (Via Email)
        Howard L. Friedberg, Esq. (Via Email)CONFIDENTIAL
TREATMENT REDACTED VERSION

 

LICENSE
AGREEMENT

BETWEEN

ADVAXIS,
INC.

(COMPANY)

AND

THE
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

(PENN)

_____

EFFECTIVE
DATE: JUNE 17,2002

 

Table
of Contents

1.
Definitions

2.
License Grant

3.
Fees and Royalties

4.
Confidentiality

5.
Term and Termination

6.
Patent Maintenance and Reimbursement

7.
Infringement And Litigation

 

8.
Disclaimer Of Warranties; Indemnification

9.
Use Of PENN's Name

10.
Additional Provisions

Attachment
1 - List
of Intellectual Property

Attachment
2 -
Joinder Agreement

Attachment
3 -
Development Plan

Attachment
4 - Stock
Purchase Agreement

Attachment
5 -
Shareholders Agreement

Attachment
6- Form
NDA

Attachment
7 - Client
and Billing Agreement

Attachment
8 -
Required Territories

 

Page 2 of
26

LICENSE
AGREEMENT

This
License Agreement ("AGREEMENT") is between The Trustees of the University of
Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at 3700
Market Street, Suite 300, Philadelphia, Pennsylvania 19104-3147 ("PENN") and
Advaxis, Inc., a corporation organized and existing under the laws of Delaware
("COMPANY"), having a place of business at 250 West Lancaster Avenue, Ste 100,
Paoli, PA 19301.

This
AGREEMENT shall be and become effective on the date (the “EFFECTIVE DATE”) on
which COMPANY raises two-hundred fifty thousand dollars ($250,000) of equity
capital or convertible debt, whereupon the COMPANY shall be deemed to have
exercised its rights under the Option (as defined below).

BACKGROUND

A. PENN
owns issued and pending U.S. and foreign patent applications based upon
information in PENN Dockets D751, H1219, H1219 - CIP, J1598, M2244, M2244 - CIP,
N2483 (which was joined with M2244), O2876 and O2883 naming Dr. Yvonne Paterson
and colleagues of PENN’s School of Medicine, as inventors; and,

B. PENN
and COMPANY have entered into a Exclusive Negotiation and Option Agreement (the
“Option”) with an effective date of March 15, 2002 and extendable upon agreement
of the parties, which grants COMPANY exclusive rights to negotiate for a license
to such pending U.S. and foreign patents and patent applications;
and,

C.
COMPANY desires to fund further research by Dr. Paterson relating to therapeutic
vaccines based on LLO-antigen fusion proteins under a sponsored research
agreement between PENN and COMPANY; and,

D.
COMPANY desires to obtain the exclusive right and license to use and exploit the
intellectual property developed by Dr. Paterson, et al, as described in
Attachment 1,
in
accordance with the DEVELOPMENT PLAN (as defined below); and,

E. PENN
has determined that commercial exploitation of the intellectual property
developed by Dr. Paterson in accordance with the terms of this AGREEMENT is in
the best interest of PENN and is consistent with its educational and research
missions; and, 

NOW,
THEREFORE, in consideration of the promises and covenants contained in this
AGREEMENT and intending to be legally bound, the parties agree as
follows:

Page 3 of
26

1.
DEFINITIONS

1.1 AFFILIATE
means, any
legal entity directly or indirectly controlling, controlled by or under common
control with COMPANY that has executed a Joinder Agreement substantially in the
form of Attachment 2 or such other form as PENN and COMPANY may hereafter agree
in writing. For purposes of this AGREEMENT, "control" means the direct or
indirect ownership of more than fifty percent (50%) of the outstanding voting
securities of a legal entity, or the right to receive more than fifty percent
(50%) of the profits or earnings of a legal entity, or the right to control the
policy decisions of a legal entity.

1.2 CALENDAR
QUARTER means each three calendar month period beginning on January 1, April 1,
July 1 and October 1, or any portion thereof, arising during the term of this
AGREEMENT.

1.3 DEVELOPMENT
PLAN means a plan for the development and/or marketing of the PENN PATENT RIGHTS
and/or PENN LICENSED PRODUCTS that reasonably demonstrates COMPANY's capability
to bring such patent rights, technical information and/or products to practical
application, as more fully described in the
Attachment 3, consisting of the following: 

1.3.1 development
activities to be undertaken, including proposed dates of completion of all major
milestones to develop and commercialize PENN LICENSED PRODUCTS;

1.3.2 a list of
all government regulatory approvals, including the nature of submissions and
government agencies involved in pre-market clearance;

1.3.3 a list of
current competitors and their competitive products, including competitors' known
plans for further development of competing technologies; and

1.3.4 anticipated
dates of first SALE of each PENN LICENSED PRODUCT described in the DEVELOPMENT
PLAN.

1.4 FAIR
MARKET VALUE means the cash consideration which COMPANY, an AFFILIATE, or any
sublicensee would realize from an unaffiliated, unrelated buyer in an arm's
length sale of an identical item sold in the same quantity and at the same time
and place of the transaction.

1.5 FIELD OF
USE means therapeutic use in humans and other mammals.

1.6 NET SALES
means the consideration or FAIR MARKET VALUE attributable to the SALE of any
PENN LICENSED PRODUCT(S), less the qualifying costs set forth below that are
directly attributable to such SALE and actually identified on the invoice and
borne by COMPANY, an AFFILIATE, or any sublicensee. Such qualifying costs shall
be limited to the following:

 

1.6.1
Discounts, in amounts customary in the trade, for quantity purchases, prompt
payments and for wholesalers and distributors.

 

Page 4 of
26

1.6.2
Credits or refunds, not exceeding the original invoice amount, for claims or
returns.

 

1.6.3
Prepaid outbound transportation expenses and transportation insurance
premiums.

 

1.6.4
Sales and use taxes and other fees, duties, and imports imposed by any
governmental agency.

1.7  PENN
LICENSED PRODUCT(S) means products which are made, made for, used or sold by
COMPANY, an AFFILIATE, or any sublicensees and which: (1) in the absence of this
AGREEMENT would infringe at least one Valid Claim or (2) use a process or
machine covered by a Valid Claim.

1.8  PENN
PATENT RIGHTS means all patents represented by or issuing from those United
States patent applications listed in Attachment 1, including continuation,
divisional and re-issue applications and any foreign counterparts and extensions
of the foregoing.

1.9 PRIMARY
STRATEGIC FIELD shall be
Cancer, including Cancer caused by infection.

1.10 SALE
means any bona fide transaction for which consideration is in fact received by
COMPANY or AFFILIATE or any sublicensee hereunder or expected for the sale, use,
lease, transfer or other disposition of PENN LICENSED PRODUCT(S). A SALE shall
be deemed completed at the time COMPANY, an AFFILIATE, or any sublicensee
invoices, ships, or receives payment for such PENN LICENSED PRODUCT(S),
whichever occurs first.

1.11 SECONDARY
STRATEGIC FIELDS includes
(a) Infectious Disease, (b) Allergy, (c) Autoimmune Disease, and (d) any other
therapeutic indications for which PENN LICENSED PRODUCT(S) are
developed.

1.12 SPONSORED
RESEARCH AGREEMENT means a sponsored research agreement between PENN and COMPANY
providing for the conduct of certain research consistent with this AGREEMENT,
all on terms and conditions acceptable to PENN and COMPANY.

1.13 VALID
CLAIM means any pending, issued or granted claim of the PENN PATENT RIGHTS that
has not been surrendered, abandoned or declared invalid or unenforceable by an
unappealed and unappealable decision of a court of competent
jurisdiction.

2.
LICENSE GRANT

2.1 PENN
grants to COMPANY for the term of this AGREEMENT an exclusive, world-wide right
and license, with the right to grant sublicenses, to make, have made, use,
import, sell and offer for sale PENN LICENSED PRODUCT(S) in the FIELD OF USE.
Except for Section 2.6, no other rights or licenses are granted. Intellectual
property created or conceived during the performance of the SPONSORED RESEACH
AGREEMENT shall be governed by the SPONSORED RESEARCH AGREEMENT.

Page 5 of
26

2.2 This
license grant is exclusive except that PENN may use and permit other not-for
profit organizations to use the PENN PATENT RIGHTS for educational and research
purposes.

2.3 COMPANY
acknowledges that pursuant to Public Laws 96-517, 97-256 and 98-620, codified at
35 U.S.C. 200-212, the United States government retains certain rights in
intellectual property funded in whole or part under any contract, grant or
similar agreement with a Federal agency. Pursuant to these laws, the government
may impose certain requirements regarding such intellectual property, including
but not limited to the requirement that products resulting from such
intellectual property sold in the United States must be substantially
manufactured in the United States. This license grant is expressly subject to
all applicable United States government rights as provided in the
above-mentioned laws and any regulations issued under those laws, as those laws
or regulations may be amended from time to time.

2.4 The right
to sublicense granted to COMPANY under this AGREEMENT is subject to the
following conditions:

2.4.1 In
each such sublicense, COMPANY must prohibit the sublicense from further
sublicensing and require that the sublicensee is subject to the terms and
conditions of the license granted to COMPANY pursuant to Section 2.1 of this
AGREEMENT, the limitations thereon set forth in Sections 2.2 , 2.3 and 2.4 as
well as sublicensee’s compliance with Sections 3.4.4, 5.5, 5.9 and 9, and
COMPANY shall impose upon its sublicensees obligations comparable to those
obligations imposed upon COMPANY pursuant to Sections 8.2 and 8.4 of this
Agreement. COMPANY may submit a written request to PENN to obtain the right to
allow a sublicensee to further sublicense on a case by case basis. Such right to
allow a sublicensee to further sublicense PENN PATENT RIGHTS shall not be
unreasonably withheld provided that COMPANY can validate to PENN’s satisfaction
that such sublicensee has the financial and resource capabilities to develop and
commercialize PENN PATENT RIGHTS and further, such sublicensee agrees that any
sub-sublicense shall be subject to the terms and conditions of the license
granted to COMPANY under this AGREEMENT.

2.4.2
Within thirty (30) days after COMPANY enters into any sublicense, COMPANY shall
deliver to PENN a complete copy of the sublicense written in the English
language. PENN's receipt of the sublicense shall not constitute an approval of
the sublicense or a waiver of any of PENN's rights or COMPANY's obligations
under this AGREEMENT.

2.4.3 In
the event of a DEFAULT under Section 5.3 hereunder all payments then or
thereafter due to COMPANY from its AFFILIATES or sublicensees in connection with
rights granted to such third party pursuant to this Agreement shall upon notice
from PENN to any such AFFILIATE or sublicensee become owed directly to PENN for
the account of COMPANY; provided however, that PENN shall remit to COMPANY the
amount by which such payments exceed the amounts owed by COMPANY to
PENN.

2.4.4 In
the event that COMPANY enters into sublicenses, COMPANY remains primarily liable
to PENN for all of COMPANY'S duties and obligations contained in this AGREEMENT,
and any act or omission of a sublicensee which would be a breach of this
AGREEMENT if performed by COMPANY shall be deemed to be a breach by COMPANY of
this AGREEMENT.

Page 6 of
26

2.5
 Promptly
after the date of execution of this AGREEMENT, PENN and COMPANY shall in good
faith negotiate the terms of, and enter into, the SPONSORED RESEARCH AGREEMENT;
provided, however, that neither PENN nor COMPANY shall be obligated to enter
into the SPONSORED RESEARCH AGREEMENT on terms that are not acceptable to such
party in all respects.

2.6 PENN
grants to COMPANY a series of exclusive options during [ * ] following the
EFFECTIVE DATE of this AGREEMENT to obtain exclusive licenses to new inventions
on therapeutic vaccines: (1) involving the use of listeria vectors and/or
listeria antigen and/or PEST-containing fusion proteins in the FIELD OF USE and
(2) developed by, under the supervision of, or in collaboration with Dr. Yvonne
Paterson; to the extent of PENN's ownership interest in any resulting
intellectual property. [ *]. Such
license agreement shall include a license initiation fee of [ * ], shall be
substantially similar in form to this AGREEMENT and shall [ * ].

2.7 PENN
grants to COMPANY a series of exclusive options during [ * ] following the
EFFECTIVE DATE of this AGREEMENT to obtain exclusive licenses to new inventions
on therapeutic vaccines: (1) involving the use of listeria vectors and/or
listeria antigen and/or PEST-containing fusion proteins in the FIELD OF USE; and
(2) developed by, under the supervision of, or in collaboration with Dr. Fred
Frankel; to the extent of PENN's ownership interest in any resulting
intellectual property. [ * ] Upon
exercise of option by COMPANY, PENN and COMPANY agree to negotiate in good faith
a comprehensive license agreement within ninety (90) days of COMPANY's exercise
of its option. Such license agreement shall include a license initiation fee of
[ * ]. 

3.
FEES AND ROYALTIES

3.1 LICENSE
INITIATION FEE AND ROYALTIES

3.1.1 In
partial consideration of the exclusive license granted to COMPANY, COMPANY shall
pay to PENN a non-refundable license initiation fee of [ * ] within thirty (30)
days of the date COMPANY receives in the aggregate [ * ] in equity financing.
The initiation fee paid to PENN pursuant to this Section shall be [ *
].

3.1.2 In
further consideration of the License, COMPANY shall perform its obligations
under that certain Stock Purchase Agreement dated April 19, 2002, between
COMPANY and PENN (“STOCK
PURCHASE AGREEMENT”), a
copy of which is attached as Attachment 4. 

3.1.3. In
further consideration of the exclusive license granted to COMPANY, COMPANY must
pay to PENN, on a quarterly basis, royalties on the annual, worldwide NET SALES
of PENN LICENSED PRODUCTS as follows:

Page 7 of
26

 

	 	
      
	
      [ *
      ]% on NET SALES in countries with pending or issued patents;
      and

	
       
	
      
	
      [ *
      ]% on NET SALES in countries without pending or issued
      patents.

However,
in the event that the PENN royalty rates represent greater than [ * ] of any
royalty payable to COMPANY by a sublicensee (on a country-by-country basis in
regard to patent status), PENN’s royalty rate shall be reduced to [ * ]of such
sublicense royalties; provided, however, that at no time will the aggregate
royalty due to PENN for any Calendar Quarter be less than [ * ]of worldwide NET
SALES of PENN LICENSED PRODUCTS. 

3.1.4.
Following the first commercial SALE of a each
PENN LICENSED PRODUCT, COMPANY must pay to PENN non-refundable minimum royalties
in advance on the following dates and in the corresponding amounts:

 

	
      Date
      Payment Becomes Due
	
      Amount

	
      the
      first January 1st arising after the
	 
	
      first
      commercial SALE
	
      $[
      * ]

	 	 
	
      the
      second January 1s arising after
	 
	
      the
      first commercial SALE
	
      $[
      * ]

	 	 
	
      the
      third and fourth January 1st
	 
	
      arising
      after the first commercial SALE
	
      $[
      * ]

 

The
obligation to pay such Minimum Royalties will not, in respect of each PENN
LICENSED PRODUCT, extend beyond January 1st of the [
* ] year following the first commercial sale of that PENN LICENSED PRODUCT. A
minimum royalty payment paid under this Section 3.1.5 shall serve as an advance
payment against royalties due under Section 3.1.3 during the period for which
such minimum royalty payment was paid.

3.1.5
COMPANY will pay PENN, on a quarterly basis, a percentage of any sublicense
initiation fee or any other non-royalty payments received by COMPANY from
sublicensees of PENN PATENT RIGHTS as follows: 

	
      If
      Sublicense Becomes Effective Anytime:
	
      Percent
      of 

      Sublicense
      Fees 

	
      On
      or before the 1st Anniversary of the EFFECTIVE DATE
	
      [ *
      ]%

	
      After
      the 1st and on or before the 2nd Anniversary
	
      [ *
      ]%

	
      of
      the EFFECTIVE DATE
	 
	
      After
      the 2nd and on or before 3rd Anniversary
	
      [ *
      ]%

	
      of
      the EFFECTIVE DATE
	 
	
      After
      the 3rd and on or before the 4th Anniversary
	
      [ *
      ]%

	
      of
      the EFFECTIVE DATE
	 
	
      After
      the 4th Anniversary of the EFFECTIVE DATE
	
      [ *
      ]%

Page 8 of
26

Such
sublicense payments include but are not limited to: i) upfront cash payments
made to COMPANY in consideration of the sublicense, but excluding funds paid to
COMPANY for research and development purposes and equity investments in COMPANY
at FAIR MARKET VALUE, and excluding equity received by COMPANY in affiliates,
joint venture partners and sublicensees; ii) "premium" over the fair market
value of equity investments in COMPANY, where "premium" is defined as the amount
by which cash amounts received by COMPANY for a particular equity security
exceed the fair market value of such security and, notwithstanding the
definition of FAIR MARKET VALUE set forth in Section 1.4 above, the fair market
value of securities shall, for purposes of this Section 3.1.5(ii), be the
average of the final “bid” and “ask” price of COMPANY's securities as of the
close of business on the last business day prior to the date such securities are
transferred to COMPANY if such securities are publicly traded or, in the event
that such securities are not traded in the public market, the fair market value,
as of the date of such securities are issued to the sublicensee, shall be
established in good faith by the COMPANY Board of Directors; and iii) the fair
market value of non-cash consideration received by COMPANY from a sublicensee
(excluding equity received by COMPANY in sublicensee), where such fair market
value, notwithstanding the definition of FAIR MARKET VALUE set forth in Section
1.4 above, is determined as of the date such consideration is received by
COMPANY and equals the fair market value determined in good faith by the COMPANY
Board of Directors

3.1.6 NET
SALES of any PENN LICENSED PRODUCT shall not be subject to more than one
assessment of the scheduled royalty; such assessment shall be the highest
applicable royalty. Where any PENN LICENSED PRODUCT is the subject of a SALE by
the COMPANY or any AFFILIATE but the COMPANY concludes in good faith that, in
the ordinary course of business, the same PENN LICENSED PRODUCT will be the
subject of a subsequent SALE by the COMPANY or any AFFILIATE for an amount
greater than the consideration paid for the previous SALE, the COMPANY may
exclude consideration paid for the previous SALE from NET SALES until the date
arising ninety (90) days after the date of the previous SALE;. If a
subsequent SALE for an amount greater than the consideration paid for the
previous SALE arises prior to such date, then the consideration paid for the
previous SALE shall be permanently excluded from NET SALES; if there is no
subsequent SALE for an amount greater than the consideration paid for the
previous SALE prior to such date, then the consideration paid for the previous
SALE shall be included in NET SALES, but shall still be credited against any
subsequent SALE of the same PENN LICENSED PRODUCT for a higher
price.

3.2 MILESTONE
PAYMENTS

The
following milestone payments are non-refundable, non-creditable, and payable to
PENN by COMPANY within forty-five (45) days following the achievement of the
following milestones as follows:

3.2.1 [ * ]
shall be due for first commercial SALE of the first PENN LICENSED PRODUCT in the
PRIMARY STRATEGIC FIELD. Such payment shall be payable as follows: [ * ] shall
be paid within forty-five (45) days of the date of the first commercial SALE, [
* ] shall be paid on the first Anniversary of the first commercial SALE; and [ *
] shall be paid on the second Anniversary of the date of the first commercial
SALE.

Page 9 of
26

3.2.2 [ * ]
shall be due and payable within forty-five (45) days following the date of the
first commercial SALE of a PENN LICENSED PRODUCT in a SECONDARY STRATEGIC FIELD;
provided,
however, that
this fee shall [ * ] for each of the SECONDARY STRATEGIC FIELDS in which PENN
LICENSED PRODUCTS are sold.

3.3 DILIGENCE
AND MAINTENANCE FEES

3.3.1
Financial Due Diligence

 

3.3.1.1 COMPANY
shall, within twelve (12) months of the EFFECTIVE DATE, raise at least [ * ] in
equity financing or convertible debt from reputable investors.

 

 

3.3.1.2
COMPANY shall, within thirty-six (36) months of the EFFECTIVE
DATE, raise
at least an additional [ * ] in equity financing or convertible debt from
reputable investors.

 

3.3.3
Developmental Due Diligence. 

3.3.3.1 COMPANY
will use commercially reasonable efforts to develop, commercialize, and market
PENN LICENSED PRODUCTS as soon as practical, consistent with the terms of the
DEVELOPMENT PLAN and any DEVELOPMENT PLAN PROGRESS REPORTS provided pursuant to
Section 3.6.1 of this AGREEMENT. The DEVELOPMENT PLAN will be prepared by
COMPANY and delivered to PENN prior to the EFFECTIVE DATE. 

 

3.3.3.2 COMPANY
agrees to commit resources (including relevant resources dedicated by
sublicensees and strategic or collaboration partners and including research
grants for Dr. Paterson) during the term of this AGREEMENT to the development
and commercialization of PENN LICENSED PRODUCTS in the PRIMARY STRATEGIC FIELD
in amounts not less than the following: 

	
      Anniversary
      of
	
      Required
      Diligence

	
      EFFECTIVE
      DATE
	
      Expenditure
      

	
      First
	
      $[
      * ]

	
      Second
	
      $[
      * ]

	
      Third
	
      $[
      * ]

	
      Fourth
	
      $[
      * ]

	
      Fifth
      and thereafter
	
      $[
      * ]

Notwithstanding
the above, COMPANY shall be not be obligated to make any due diligence
expenditures at any time after the date the COMPANY first becomes obligated to
pay minimum royalties pursuant to Section 3.1.5. In the event that total
expenditures for the development and commercialization of PENN LICENSED PRODUCTS
do not meet or exceed the amounts set forth above, COMPANY must pay to PENN the
difference between the mandated amount listed above and the actual amount
expended by COMPANY and/or its sublicensees, strategic or collaboration
partner(s). Funds invested in development in a given year that are in excess of
the above amounts shall be creditable up to $[ * ] against the diligence
requirements of the following year.

Page 10 of
26

3.3.3.3 SECONDARY
STRATEGIC FIELDS: By [ * ] of the EFFECTIVE DATE, COMPANY must either (i)
initiate research and development programs for the SECONDARY STRATEGIC FIELDS of
infectious disease, allergy, and autoimmune disease, at an initial annual
expense level of at least [ * ] per field, or (ii) partner with or grant one or
more third parties rights for the commercial development of PENN LICENSED
PRODUCTS in one or more of such SECONDARY STRATEGIC FIELDS.

3.3.3.4 In the
event COMPANY develops PENN LICENSED PRODUCTS in any SECONDARY STRATEGIC FIELDS
pursuant to Section 3.3.3.3, part (i), the parties will negotiate in good faith
due diligence requirements for subsequent years for such SECONDARY STRATEGIC
FIELD under development at that time. If COMPANY fails to complete either part
(i) or (ii) as described in Section 3.3.3.3 above for such SECONDARY STRATEGIC
FIELD(S) by [ * ]
anniversary of the EFFECTIVE DATE, COMPANY will forfeit all rights for
development of commercial products in such SECONDARY STRATEGIC FIELDS, and
rights will return to PENN for such SECONDARY STRATEGIC FIELD(S). PENN will
thereafter be free to enter into agreements for such forfeited rights with any
third party for commercial development in the respective SECONDARY STRATEGIC
FIELD(S).

3.3.6 COMPANY
must pay to PENN annual license maintenance fees, according to the following
schedule: 

Due
Date:                 Amount:

1st
anniversary of EFFECTIVE DATE            $[ *
]  

 

2nd
anniversary of EFFECTIVE DATE            $[ *
]

 

3rd
anniversary of EFFECTIVE DATE            $[ *
]

 

4th
anniversary of EFFECTIVE DATE            $[ *
]

 

5th
anniversary of EFFECTIVE DATE            $[ *
]

 

6th
anniversary of EFFECTIVE DATE            $[ *
]

and each
anniversary thereafter    

provided,
however, that
such fees shall not be payable on any anniversary of the EFFECTIVE DATE arising
at any time after the first commercial SALE of a PENN LICENSED
PRODUCT.

Page 11 of
26

3.4 REPORTS
AND RECORDS

3.4.1 On each
December 1 arising during the term of this AGREEMENT, COMPANY must provide PENN
with written progress reports,
(each a
“DEVELOPMENT PLAN PROGRESS REPORT”), setting forth COMPANY'S progress regarding
its efforts to develop and commercialize PENN LICENSED PRODUCTS, including
activities of AFFILIATES and sublicensees, for the preceding year. COMPANY shall
also notify PENN within thirty (30) days of the first commercial SALE by the
COMPANY, an AFFILIATE, or any sublicensee of each PENN LICENSED PRODUCT. Each
DEVELOPMENT PLAN PROGRESS REPORT shall include, without limitation:

3.4.1.1 The date
of the DEVELOPMENT PLAN PROGRESS REPORT and the time covered by such
report.

3.4.1.2 Major
activities and accomplishments completed by COMPANY, any AFFILIATE or any
sublicensee since the last DEVELOPMENT PLAN PROGRESS REPORT.

3.4.1.3
Significant research and development projects currently being performed by
COMPANY, any AFFILIATE, or any sublicensee and projected dates of
completion.

3.4.1.4
Future development activities expected to be undertaken by COMPANY, any
AFFILIATE, or any sublicensee during the next reporting period.

 

3.4.1.5
Current development stage (e.g., pre-clinical, Phase I, Phase II or Phase II) of
each PENN LICENSED PRODUCT and targeted date of NDA approval, if
any.

3.4.1.6
Significant changes to the DEVELOPMENT PLAN, including the reasons for the
changes.   

3.4.1.7
Summary of development efforts related to PENN PATENT RIGHTS being performed by
third parties including the nature of the relationship between the COMPANY
and such third parties.

3.4.2 COMPANY
must deliver to PENN within forty-five (45) days after the end of each CALENDAR
QUARTER a report, certified by the chief financial officer of COMPANY, setting
forth the calculation of the royalties due to PENN for such CALENDAR QUARTER,
including, without limitation:

3.4.2.1 Number of
PENN LICENSED PRODUCTS involved in SALES, listed by country.

 

3.4.2.2 Gross
consideration for SALES of PENN LICENSED PRODUCTS, including all amounts
invoiced, billed, or received.

 

3.4.2.3 Qualifying
costs, as defined in Section 1.5, listed by category of cost.

 

Page 12 of
26

3.4.2.4 NET SALES
of PENN LICENSED PRODUCTS listed by country.

 

3.4.2.5 Royalties
owed to PENN, listed by category, including without limitation earned,
sublicensee-derived, and minimum royalty categories.

 

3.4.2.6 Earned
royalty amounts credited against minimum royalty payments. 

3.4.3 COMPANY
must pay the royalties due under Sections 3.1 and 3.3 within forty-five (45)
days following the last day of the CALENDAR QUARTER in which the royalties
accrue. COMPANY must send with the royalties the report described in Section
3.4.1.

3.4.4 COMPANY
must maintain and cause its AFFILIATES and any sublicensees to maintain,
complete and accurate books and records which enable the royalties, fees, and
payments payable under this AGREEMENT to be verified. The records for each
CALENDAR QUARTER must be maintained for five (5) years after the submission of
each report provided pursuant to Section 3.4.2. Upon reasonable prior notice to
COMPANY, COMPANY must provide an independent auditor appointed by PENN and
reasonably acceptable to COMPANY with access to all books and records relating
to the SALES of PENN LICENSED PRODUCTS by COMPANY and its AFFILIATES or any
sublicensees in order to conduct a review or audit of those books and records.
Access to these books and records pertaining to NET SALES must be made available
following the date of the first product sale and then no more than once every
three (3) years following each audit during the term of this AGREEMENT, during
normal business hours, and on two (2) occasions during the three (3) year period
immediately following expiration or termination of this AGREEMENT. If a review
or audit of the [ * ] or more, COMPANY must reimburse to PENN its actual
out-of-pocket costs of employing its auditors in connection with such review or
audit. Notwithstanding the foregoing, COMPANY agrees to conduct, at its expense,
an independent audit of SALES and royalties at least every five (5) years once
annual SALES of a PENN LICENSED PRODUCT are greater than [ * ]. The audit shall
address, at a minimum, the amount of gross sales by or on behalf of COMPANY
during the audit period, the amount of funds owed to PENN under this AGREEMENT,
and whether the amount owed has been paid to PENN and is reflected in the
records of the COMPANY. A report by the auditors shall be submitted promptly to
PENN upon completion.

3.4.5 COMPANY
shall provide to PENN, at
least as frequently as they are distributed to the Board of Directors and/or
management of COMPANY, copies of: all Board and managerial reports that relate
to the PENN
PATENT RIGHTS and
PENN
LICENSED PRODUCTS; and all
business plans, projections and financial statements that are distributed to the
Board of Directors and/or management.

3.5 CURRENCY,
PLACE OF PAYMENT, INTEREST, PAYMENT OF EXPENSES

3.5.1 All
dollar amounts referred to in this AGREEMENT are expressed in United States
dollars. All payments to PENN under this AGREEMENT must be made in United States
dollars by check payable to "The Trustees of the University of Pennsylvania" and
sent to the following address: 

Page 13 of
26

The
Trustees of the University of Pennsylvania

[ *
]

For
electronic transfer, all payments should be sent to the following
address:

[ *
]

3.5.2 If
COMPANY receives revenues from SALES of PENN LICENSED PRODUCTS in currency other
than United States dollars, such revenues shall, for purposes of calculating NET
SALES, be converted into United States dollars at the conversion rate for the
foreign currency as published in the eastern edition of The Wall Street Journal
as of the last business day of the CALENDAR QUARTER in which such NET SALES were
accrued.

3.5.3 Amounts
that are not paid when due shall accrue interest from the due date until paid,
at a rate equal to [ * ] per month (or the maximum allowed by law, if
less).

4.
CONFIDENTIALITY

4.1 CONFIDENTIAL
INFORMATION means and includes all technical information, inventions,
developments, discoveries, software, know-how, methods, techniques, formulae,
data, processes and other proprietary ideas, whether or not patentable or
copyrightable, that PENN identifies as confidential or proprietary at the time
it is delivered or communicated to COMPANY.

4.2
COMPANY agrees to maintain in confidence and not to disclose to any third party
any CONFIDENTIAL INFORMATION of PENN. COMPANY agrees to ensure that its
employees have access to CONFIDENTIAL INFORMATION only on a need-to-know basis
and are obligated in writing to abide by COMPANY's obligations under this
AGREEMENT. The foregoing obligation shall not apply to:

4.2.1
information that is known to COMPANY or independently developed by COMPANY prior
to the time of disclosure, in each case, to the extent evidenced by written
records promptly disclosed to PENN upon receipt of the CONFIDENTIAL
INFORMATION;

4.2.2
information disclosed to COMPANY by a third party that has a right to make such
disclosure;

4.2.3
information that becomes patented, published or otherwise part of the public
domain as a result of acts by PENN or a third person obtaining such information
as a matter of right; or 

Page 14 of
26

4.2.4  information
that is required to be disclosed by order of United States governmental
authority or a court of competent jurisdiction; provided that COMPANY must use
best efforts to obtain confidential treatment of such information by the agency
or court.

4.2.5  information
disclosed by COMPANY to a third party under the normal course of business,
provided that COMPANY discloses such information under confidentiality
agreements that are substantially in the form of Attachment 6 or such other form
as PENN may from time-to-time approve.

4.3 PENN
shall not be obligated to accept any confidential information from COMPANY. PENN
shall use best efforts not to disclose confidential information of COMPANY that
is received by PENN’s Center for Technology Transfer from COMPANY to any third
party (subject to the exceptions analogous to those in Section 4.2). PENN bears
no institutional responsibility for maintaining the confidentiality of any
CONFIDENTIAL INFORMATION other than (i) reports provided pursuant to Sections
3.4.1. and 3.4.2, and (ii)
any information disclosed to PENN's auditor pursuant to Section
3.4.4..

4.4 PENN
acknowledges that COMPANY is free to enter into confidentiality agreements with
any faculty members or other employees or students of PENN provided such
agreements are acceptable to the relevant faculty members, employees or students
and are substantially in the form of Attachment 6 or such other form as PENN may
from time-to-time approve. 

5.
TERM AND TERMINATION

5.1 This
AGREEMENT, unless sooner terminated as provided in this AGREEMENT, terminates
upon the later of: (a) expiration of the last to expire or become abandoned of
the PENN PATENT RIGHTS; or (b) twenty (20) years after the EFFECTIVE
DATE.

5.2 COMPANY
may, upon sixty (60) days written notice to PENN, terminate this AGREEMENT by
doing all of the following:

5.2.1
ceasing to make, have made, use, import, sell and offer for sale all PENN
LICENSED PRODUCTS; and

5.2.2
terminating all sublicenses, and causing all AFFILIATES and sublicensees to
cease making, having made, using, importing, selling and offering for sale all
PENN LICENSED PRODUCTS; and

5.2.3
paying all monies owed to PENN under this AGREEMENT and the SPONSORED RESEARCH
AGREEMENT, if any.

 

5.3 PENN may
terminate this AGREEMENT if any of the following events of default (“DEFAULT”)
occur:

 

Page 15 of
26

5.3.1
COMPANY is late in paying to PENN royalties, expenses, or any other monies due
under this AGREEMENT and COMPANY does not pay PENN in full within ninety (90)
days of written demand for such payment; or

5.3.2
COMPANY, experiences a Trigger Event (as defined below); or

5.3.3
COMPANY, or any AUTHORIZED AFFILIATE is in material breach of this AGREEMENT and
such breach is not cured within ninety
(90) sixty
(60) days after written notice of the breach is provided to
COMPANY.

 

5.4
 Trigger
Event means any of the following:

 

 

5.4.1
If
COMPANY,

 

 

5.4.1.1
becomes insolvent, bankrupt or generally fails to pay its debts as such debts
become due; 

 

 

5.4.1.2
is adjudicated insolvent or bankrupt; admits in writing its inability to pay its
debts; or shall suffer a custodian, receiver or trustee for it or substantially
all of its property to be appointed and, if appointed without its consent, not
be discharged within thirty (30) days; or

 

 

5.4.1.3
makes an assignment for the benefit of creditors; or suffers proceedings under
any law related to bankruptcy, insolvency, liquidation or the reorganization,
readjustment or the release of debtors to be instituted against it and, if
contested by it, not dismissed or stayed within ten (10) days; 

 

 

5.4.2 If
proceedings under any law related to bankruptcy, insolvency, liquidation, or the
reorganization, readjustment or the release of debtors are instituted or
commenced by COMPANY; 

 

 

5.4.3 If any
order for relief is entered relating to any of the proceedings described in
Sections 5.4.1 or 5.4.; 

 

 

5.4.4 If
COMPANY shall call a meeting of its creditors with a view to arranging a
composition or adjustment of its debts;

 

5.4.5 If any
sublicensee experiences an event comparable to a TRIGGER EVENT or is in material
breach of its sublicense and fails to cure such material breach within sixty
(60) days of COMPANY's written notice thereof, and (i) such sublicensee is
either (x) responsible for a material amount of NET SALES or (y) primarily
responsible for research and/or development activities relating to any
contemplated PENN LICENSED PRODUCT described in the DEVELOPMENT PLAN and
anticipated to result in commercial SALES having a positive material effect on
NET SALES, and (ii) COMPANY fails to use commercially reasonable efforts to
exercise its termination rights under the relevant sublicense;

Page 16 of
26

5.4.6 If any
AFFILIATE experiences an event comparable to a TRIGGER EVENT and (i) such
AFFILIATE is either (x) responsible for a material amount of NET SALES or (y)
primarily responsible for research and/or development activities relating to any
contemplated PENN LICENSED PRODUCT described in the DEVELOPMENT PLAN and
anticipated to result in commercial SALES having a positive material effect on
NET SALES, and (ii) COMPANY fails to use commercially reasonable efforts to
exercise its termination rights under any applicable agreements between COMPANY
and such AFFILIATE implicating the rights granted to COMPANY under this
AGREEMENT or otherwise deprive such AFFILIATE of any responsibility for the
development or commercialization of PENN LICENSED PRODUCTS; or

5.4.7 If,
without PENN's express prior written consent, COMPANY grants a sublicense to. or
otherwise subsequently conducts material business implicating COMPANY's rights,
duties and obligations under this AGREEMENT with, any Affiliate or sublicensee
whose agreement or commercial relationship with COMPANY was previously
terminated by COMPANY as contemplated in Sections 5.4.5 or 5.4.6 above.

5.5 In the
event of a termination under Section 5.3 above, all duties of PENN and all
rights (but not duties) of COMPANY under this AGREEMENT immediately terminate
without the necessity of any action being taken either by PENN or by COMPANY.
Upon and after any termination of this Agreement, COMPANY, any AFFILIATE, and
any sublicensee shall refrain from further manufacture, sale, marketing,
importation and/or distribution of PENN
LICENSED PRODUCT(s). If,
upon a termination of this agreement by PENN, a sublicensee is not in breach of
its sublicense agreement and did not cause the Trigger Event, than PENN shall
agree to negotiate in good faith with sublicensee a license agreement having
commercially-reasonable terms.

5.6 Upon
termination of this AGREEMENT, COMPANY must, at PENN's request, return to PENN
all CONFIDENTIAL INFORMATION in respect of which COMPANY is RECIPIENT, together
with any data generated by COMPANY during the term of this AGREEMENT which will
facilitate the further development of the Technology licensed to COMPANY
hereunder (the “NEW COMPANY DATA”). Upon termination of this AGREEMENT, COMPANY
agrees to negotiate in good faith a license granting to potential licensees
identified by PENN rights in the NEW COMPANY DATA on commercially reasonable
terms.

5.7 COMPANY's
obligation to pay all monies owed but not yet paid under this AGREEMENT shall
survive termination of this AGREEMENT. In addition, the provisions of Sections
3.4.2, 3.4.3, 3.4.4 and 3.5, Articles 4 - Confidentiality, Article 5 - Term and
Termination, Article 8 - Disclaimer of Warranties; Indemnification, Article 9 -
Use of PENN's Name; and Article 10 - Additional Provisions shall survive such
termination in accordance with their respective terms.

 

5.8 Upon
termination of this AGREEMENT, COMPANY shall cause physical inventories to be
taken immediately of: (a) all completed PENN
LICENSED PRODUCT(s) on
hand under the control of COMPANY, any AFFILIATES, or any sublicensees; and (b)
such PENN
LICENSED PRODUCT(s) as
are in the process of manufacture and component parts thereof as of the date of
termination of this AGREEMENT, which inventories shall be reduced to writing.
COMPANY shall deliver copies of such written inventories, verified by an officer
of COMPANY forthwith to PENN.
PENN shall
have 45
forty-five (45) days after receipt of such verified inventories within which to
challenge the inventory and request an audit. Upon five (5) days written notice
to COMPANY, PENN and its
agents shall be given access during business hours to the premises of COMPANY
and/or AFFILIATES or sublicensees for the purpose of conducting an audit. Upon
the termination of this AGREEMENT, COMPANY shall, at its own expense forthwith
remove and promptly upon PENN’s request, efface or destroy all references to
PENN from all
advertising or other materials used in the promotion of COMPANY’s business or
the business of any AFFILIATE or sublicensee and COMPANY, its AFFILIATES, and
any sublicensee shall not thereafter represent in any manner that it has rights
in or to the PENN
PATENT RIGHTS or
PENN
LICENSED PRODUCT(s).

 

Page 17 of
26

5.9 Notwithstanding
the foregoing, if this AGREEMENT terminates other than pursuant to Section 5.4.1
or 5.4.2, COMPANY shall have a period of six (6) months to sell off its
inventory of PENN
LICENSED PRODUCT(s)
existing on the date of termination of this AGREEMENT and shall pay royalties to
PENN with
respect to such PENN
LICENSED PRODUCT(s)
within thirty (30) days following the expiration of such six-month period (“Sell
Off Right”).

6.
PATENT MAINTENANCE AND REIMBURSEMENT

6.1 Subject
to this Article 6, PENN controls the prosecution and maintenance of PENN PATENT
RIGHTS. COMPANY must reimburse PENN for all documented attorneys fees, expenses,
official fees and other charges incurred after the EFFECTIVE DATE of the option
and incident to the preparation, prosecution maintenance and licensing of PENN
PATENT RIGHTS. COMPANY's obligation to reimburse such costs shall commence as of
the date COMPANY closes an initial [ * ] or greater financing round;
reimbursements shall be paid within thirty (30) days after COMPANY’S receipt of
invoices for such fees, expenses and charges

 6.2 COMPANY
shall reimburse PENN for all historically accrued patent and licensing expenses,
attorneys fees, official fees and all other charges incident to the preparation,
prosecution and maintenance of the PENN PATENT RIGHTS that were incurred before
the EFFECTIVE DATE of the Option (March 15, 2002) within thirty (30) days after
the date of closing of an initial [ * ] or greater financing round. Such
historically accrued expenses are estimated by PENN at approximately [ * ] but
will not be greater than [ * ].

6.3 Notwithstanding
Section 6.1, COMPANY [ * ]. In that event, PENN shall be the client of the
attorney, and COMPANY may directly manage the prosecution of the PENN PATENT
RIGHTS through a Client and Billing Agreement attached hereto as Attachment 7
(the "CLIENT AND BILLING AGREEMENT");. COMPANY
shall bear all costs of prosecution of the PENN PATENT RIGHTS. PENN shall be
copied on all correspondence related to the prosecution of the PENN PATENT
RIGHTS between COMPANY and the selected attorney, and retains the right to
advise COMPANY regarding patent prosecution. PENN and COMPANY shall in good
faith cooperate to implement the prosecution and maintenance of PENN PATENT
RIGHTS in accordance with the CLIENT AND BILLING AGREEMENT and COMPANY must
promptly pay for all ongoing attorneys fees, expenses, official fees and all
other charges incident to the preparation, prosecution and maintenance of the
PENN PATENT RIGHTS after the EFFECTIVE DATE of this AGREEMENT in accordance with
such CLIENT AND BILLING AGREEMENT. 

Page 18 of
26

6.4 COMPANY
hereby covenants and agrees that it shall in good faith prosecute PENN PATENT
RIGHTS in all countries set forth in Attachment 7 (the “REQUIRED TERRITORIES”);
[ * ]; If COMPANY refuses such expenditures under the CLIENT AND BILLING
AGREEMENT, or does not reimburse PENN for expenses related to PENN PATENT
RIGHTS, COMPANY’S rights in the relevant PENN PATENT RIGHTS granted under
Section 2.1 of this AGREEMENT shall,
thereafter terminate on a patent-by-patent basis. Thereafter, (i) PENN
will, be free,
at its discretion and expense, to either abandon such applications or patents or
to continue such preparation, prosecution and/or maintenance activities; and
(ii) PENN may,, license
such PENN PATENT RIGHTS to any third party upon such terms and conditions as
PENN deems appropriate.

6.5 [ *
]

6.6 [ *
]

6.7 COMPANY
may at its sole discretion (i) apply for and obtain such extension, term
restoration or comparable addition to the life of the affected PENN PATENT
RIGHTS and (ii) apply for and obtain such supplemental protection certificates
for the approved product or process covered by the PENN PATENT RIGHTS, all to
the extent the same are available pursuant to the applicable laws and
regulations of the jurisdiction where such regulatory approval is given. Nothing
herein shall be construed to obligate COMPANY to in fact seek extension or
restoration of any PENN PATENT RIGHTS or supplemental protection for any PENN
LICENSED PRODUCTS. Where COMPANY applies for and obtains supplemental protection
or comparable treatment for any PENN LICENSED PRODUCT, then, subject to
continued payment by COMPANY of its royalty obligations under this AGREEMENT,
this AGREEMENT shall not expire pursuant to Section 5.1(a) prior to the date of
termination of such supplemental protection or comparable
treatment.

6.8 Notwithstanding
the other provisions of this Article 6, COMPANY shall in good faith confer with,
and regularly keep PENN apprised of, its patent prosecution, maintenance,
enforcement and defense strategy and plans and shall in good faith consider
PENN's comments regarding such strategy and plans including, without limitation,
the following:

6.8.1 Providing
to PENN, promptly upon PENN's request, copies of any office actions or proposed
responses to office actions affecting PENN PATENT RIGHTS.

6.8.2 Providing
to PENN, promptly upon PENN's request, copies of any written communications
alleging infringement of, or responding to allegations of infringement of, the
PENN PATENT RIGHTS by third parties and any pleadings, motions, briefs or other
substantive papers filed by COMPANY or any third parties or proposed to be filed
by COMPANY, in connection with any litigation, arbitration or regulatory
proceedings (including interference and opposition proceedings).

Page 19 of
26

7.
INFRINGEMENT AND LITIGATION

7.1 PENN and
COMPANY are responsible for notifying each other promptly of any infringement of
PENN PATENT RIGHTS which may come to their attention. PENN and COMPANY shall
consult one another in a timely manner concerning any appropriate response to
the infringement.

  7.2 COMPANY
may prosecute such infringement at its own expense. COMPANY must not settle or
compromise any such suit in a manner that imposes any obligations or
restrictions on PENN or grants any rights to the or the PENN PATENT RIGHTS,
without PENN's prior written permission. Financial recoveries from any such
litigation will first be applied to reimburse COMPANY for its litigation
expenditures with additional recoveries being paid to COMPANY, subject to a
royalty due PENN based on the provisions of Article 3. 

7.3 COMPANY's
rights under Section 7.2 are subject to the continuing right of PENN to
intervene at PENN's own expense and join COMPANY in any claim or suit for
infringement of the PENN PATENT RIGHTS. Any consideration received by COMPANY in
settlement of any claim or suit shall be shared between PENN and COMPANY in
proportion with their share of the litigation expenses in such infringement
action.

7.4 Subject
to COMPANY’S obligations under Section 6.7 above, COMPANY shall be free to
determine at its sole discretion when, if at all, and how to assert and
prosecute infringement claims relating to PENN PATENT RIGHTS where such
determinations are based upon bona
fide
strategic issues such as COMPANY’S concerns regarding challenges to the validity
of the PENN PATENT RIGHTS. If COMPANY elects at its sole discretion not to
prosecute or otherwise abate any infringement for non-strategic
reasons , COMPANY
shall so notify PENN, and PENN may thereafter prosecute such infringement at its
own expense. In such event, financial recoveries will be entirely retained by
PENN. 

7.5 In any
action to enforce any of the PENN PATENT RIGHTS, either party, at the request
and expense of the other party shall cooperate to the fullest extent reasonably
possible. This provision shall not be construed to require either party to
undertake any activities, including legal discovery, at the request of any third
party except as may be required by lawful process of a court of competent
jurisdiction.

7.6 [ *
..]

Page 20 of
26

8.
DISCLAIMER OF WARRANTIES; INDEMNIFICATION

8.1 THE PENN
PATENT RIGHTS, PENN LICENSED PRODUCTS AND ALL OTHER TECHNOLOGY LICENSED UNDER
THIS AGREEMENT ARE PROVIDED ON AN "AS IS" BASIS AND PENN MAKES NO
REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO. BY WAY
OF EXAMPLE BUT NOT OF LIMITATION, PENN MAKES NO REPRESENTATIONS OR WARRANTIES
(i) OF COMMERCIAL UTILITY; (ii) OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE; OR (iii) THAT THE USE OF THE PENN PATENT RIGHTS, PENN LICENSED PRODUCTS
AND ALL TECHNOLOGY LICENSED UNDER THIS AGREEMENT WILL NOT INFRINGE ANY PATENT,
COPYRIGHT OR TRADEMARK OR OTHER PROPRIETARY RIGHTS OF OTHERS. PENN SHALL NOT BE
LIABLE TO COMPANY, COMPANY'S SUCCESSORS OR ASSIGNS OR ANY THIRD PARTY WITH
RESPECT TO: ANY CLAIM ARISING FROM COMPANY'S USE OF THE PENN PATENT RIGHTS, PENN
LICENSED PRODUCTS AND ALL TECHNOLOGY LICENSED UNDER THIS AGREEMENT OR FROM THE
MANUFACTURE, USE OR SALE OF PENN LICENSED PRODUCTS. NEITHER PARTY SHALL BE
LIABLE TO THE OTHER FOR ANY CLAIM FOR LOSS OF PROFITS, LOSS OR INTERRUPTION OF
BUSINESS, OR FOR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND
REGARDLESS OF THE CAUSE OF ACTION OR THEORY OF LIABILITY UPON WHICH SUCH CLAIM
IS BASED, AND WHETHER OR NOT THE PARTY AGAINST WHOM SUCH CLAIM IS MADE WAS AWARE
OF THE POSSIBILITY OF SUCH DAMAGES.

8.2 COMPANY
must defend, indemnify and hold harmless PENN, its trustees, officers, agents
and employees (individually, an "Indemnified Party", and collectively, the
"Indemnified Parties"), from and against any and all liability, loss, damage,
action, claim or expense suffered or incurred by the Indemnified Parties
(including attorney's fees) (individually, a "Liability", and collectively, the
"Liabilities") that results from or arises out of third-party claims made in
connection with: (a) the development, use, manufacture, promotion, sale or other
disposition of any PENN PATENT RIGHTS or PENN LICENSED PRODUCTS by COMPANY, its
assignees, AFFILIATES, sublicensees, vendors or other third parties; (b) any
breach by COMPANY of this AGREEMENT, as well as any Liabilities resulting from
the enforcement by an Indemnified Party of this Section. Without limiting the
foregoing, COMPANY must defend, indemnify and hold harmless the Indemnified
Parties from and against any Liabilities resulting from:

8.2.1 any
product liability or other claim of any kind made by a third party and related
to the use by a third party of a PENN LICENSED PRODUCT that was manufactured,
sold or otherwise disposed by COMPANY, its assignees, AFFILIATES, sublicensees,
vendors or other third parties;

8.2.2 a
claim by a third party that the PENN PATENT RIGHTS or the design, composition,
manufacture, use, sale or other disposition of any PENN LICENSED PRODUCT
infringes or violates any patent, copyright, trademark or other intellectual
property rights of such third party; and

Page 21 of
26

8.2.3
claims made by third parties (including governmental agencies) in connection
with clinical trials or studies conducted by or on behalf of COMPANY relating to
the PENN PATENT RIGHTS or PENN LICENSED PRODUCTS, including, without limitation,
any claim by or on behalf of a human subject of any such clinical trial or
study.

8.3 COMPANY
is not permitted to settle or compromise any claim or action giving rise to
Liabilities in a manner that imposes any restrictions or obligations on PENN or
grants any rights to the PENN PATENT RIGHTS or PENN LICENSED PRODUCTS
without  PENN’s
prior written consent. If COMPANY fails or declines to assume the defense of any
such claim or action within thirty (30) days after notice thereof, PENN may
assume the defense of such claim or action for the account and at the risk of
COMPANY for indemnification, and any Liabilities related thereto shall be
conclusively deemed a liability of the party responsible for indemnification.
The indemnification rights of PENN or any other Indemnified Parties are in
addition to all other rights which such Indemnified Party may have at law or in
equity or otherwise.

8.4 INSURANCE

8.4.1
Within 90 days of the EFFECTIVE DATE of this AGREEMENT, COMPANY must procure and
maintain a policy or policies of comprehensive general liability insurance,
including broad form and contractual liability, in a minimum amount of
$2,000,000 combined single limit per occurrence and in the aggregate as respects
personal injury, bodily injury and property damage arising out of COMPANY's
performance under this AGREEMENT.

8.4.2
COMPANY must, upon commencement of clinical trials involving PENN LICENSED
PRODUCTS, procure and maintain a policy or policies of product liability
insurance in a minimum amount of $3,000,000 combined single limit per occurrence
and in the aggregate as respects bodily injury and property damage arising out
of COMPANY's performance under this AGREEMENT.

8.4.3 The
policy or policies of insurance described in this Section 8.4 [must be issued by
an insurance carrier with an AM Best rating of “A” or better and] must name PENN
as an additional insured with respect to COMPANY's performance of this
AGREEMENT. COMPANY must provide PENN within thirty (30) days of the EFFECTIVE
DATE with certificates evidencing the insurance coverage required herein. Such
certificates must provide that COMPANY's insurance carrier(s) notify PENN in
writing at least 30 days prior to cancellation or material change in
coverage.

8.4.4
PENN may periodically review the adequacy of the minimum limits specified above
and reserves the right to require COMPANY to adjust the liability coverages,
provided such adjustments do not require COMPANY to obtain coverages in excess
of those customarily obtained by entities incurring comparable risks in
comparable industries. The specified minimum insurance amounts do not constitute
a limitation on COMPANY's obligation to indemnify PENN under this
AGREEMENT.

Page 22 of
26

9.
USE OF PENN'S NAME

COMPANY
and its employees and agents must not use and COMPANY must not permit its
AFFILIATES or sublicensees to use PENN's name or any adaptation thereof, or any
PENN seal, logotype, trademark, or service mark, or the name, mark, or logotype
of any PENN representative or organization in any way without the prior written
consent of PENN.

10.
ADDITIONAL PROVISIONS

10.1 Nothing
in this AGREEMENT shall be deemed to establish a relationship of principal and
agent between PENN and COMPANY, nor any of their agents or employees for any
purpose whatsoever, nor shall this AGREEMENT be construed as creating any other
form of legal association or arrangement which would impose liability upon one
party for the act or failure to act of the other party.

10.2 COMPANY
is not permitted to assign this AGREEMENT or any part of it, either directly or
by merger or other operation of law, without the prior written consent of PENN,
which consent shall not be unreasonably withheld. A withholding of PENN’s
consent shall be considered as reasonable in the event that the acquiring party
of the assignee of this license is not reputable or is not capable of developing
the PENN PATENT RIGHTS in the FIELD OF USE. Any prohibited assignment of this
AGREEMENT or the rights hereunder shall be null and void. No assignment relieves
COMPANY of responsibility for the performance of any accrued obligations which
it has prior to such assignment.

10.3  A waiver
by either party of a breach of any provision of this AGREEMENT will only be
valid if express, in writing and signed by an authorized representative of the
waiving party and will not constitute a waiver of any subsequent breach of that
provision or a waiver of any breach of any other provision of this
AGREEMENT.

10.4 Notices,
payments, statements, reports and other communications under this AGREEMENT
shall be in writing and shall be deemed to have been received as of the date
sent if sent by public courier (e.g. Federal Express) or by Express Mail,
receipt requested, and addressed as follows:

	
      If
      for PENN:
	
      with
      a copy to:

	 	 
	
      University
      of Pennsylvania
	
      Office
      of General Counsel

	
      Center
      for Technology Transfer
	
      University
      of Pennsylvania

	[ *
      ]	
       

	 	 
	
      If
      for COMPANY:
	
      with
      a copy to:

	 	 
	
      Advaxis,
      Inc.
	
      Pryor
      Cashman Sherman & Flynn

	
      250
      West Lancaster Ave., Ste. 100
	
      410
      Park Avenue, 10th Floor

	
      Paoli,
      PA 19301
	
      New
      York, NY 10022

	
      Attn:
      Mr. James P. Patton
	
      Attn:
      Selig D. Sacks, Esq.

Page 23 of
26

Either
party may change its official address upon written notice to the other
party.

10.5 This
AGREEMENT shall be construed and governed in accordance with the laws of the
Commonwealth of Pennsylvania, without giving effect to conflict of law
provisions. In the event that a party to this AGREEMENT perceives the existence
of a dispute with the other party concerning any right or duty provided for
herein, the parties will, as soon as practicable, confer in an attempt to
resolve the dispute. If the parties are unable to resolve such dispute amicably,
then the parties hereby submit to the exclusive jurisdiction of and venue in the
courts located in the Eastern District of the Commonwealth of Pennsylvania with
respect to any and all disputes concerning the subject of this
AGREEMENT.

10.6 PENN
and COMPANY shall not discriminate against any employee or applicant for
employment because of race, color, sex, sexual or affectional preference, age,
religion, national or ethnic origin, handicap, or because he or she is a
disabled veteran or a veteran of the Vietnam Era.

10.7 COMPANY
must comply with all prevailing laws, rules and regulations that apply to its
activities or obligations under this AGREEMENT. Without limiting the foregoing,
it is understood that this AGREEMENT may be subject to United States laws and
regulations controlling the export of technical data, computer software,
laboratory prototypes and other commodities, articles and information, including
the Arms Export Control Act as amended in the Export Administration Act of 1979,
and that the parties’ obligations are contingent upon compliance with applicable
United States export laws and regulations. The transfer of certain technical
data and commodities may require a license from the cognizant agency of the
United States Government and/or written assurances by COMPANY that COMPANY shall
not export data or commodities to certain foreign countries without prior
approval of such agency. PENN neither represents that a license is not required
nor that, if required, it will issue.

10.8 If any
provision of this AGREEMENT shall be
held to be illegal, invalid or unenforceable, then such illegality, invalidity
or unenforceability shall attach only to such provision and shall not in any
manner affect or render illegal, invalid or unenforceable any other provision of
this AGREEMENT, and
this AGREEMENT shall be
carried out as if any such illegal, invalid or unenforceable provision were not
contained herein.

10.9 This
AGREEMENT embodies
the entire agreement of the parties with respect to the matters herein
contained, and supercedes all prior oral or written agreements relating thereto
except to the extent expressly addressed in the STOCK
PURCHASE AGREEMENT or the
STOCKHOLDER’S
AGREEMENT. Any
modification of this AGREEMENT must be in writing and signed by an authorized
representative of each party.

Page 24 of
26

  IN
WITNESS WHEREOF, the parties, intending to be legally bound, have caused this
AGREEMENT to be executed by their duly authorized representatives.

	THE TRUSTEES OF
      THE     
      UNIVERSITY
      OF PENNSYLVANIA
	 	 	 ADVAXIS,
  INC.
	 	 	 	 
	 	 	 	 
	SIGNATURE: /s/
      Louis P. Berneman	 	 	
      SIGNATURE: 
      /s/ J. Todd Derbin 

	
      

    	 	 	
      

    
	
      TYPED
      NAME:
      Louis P. Berneman 

      TITLE:
      Managing Director   

      Center
      for Technology Transfer 
	 	 	
      TYPED
      NAME:  J.
      Todd Derbin 

TITLE:  
	 DATE:	 	 	 DATE:

 

 

Page 25 of
26

ATTACHMENT
1 - List of Intellectual Property

[
* ]

ATTACHMENT
2 - Sponsored Research Agreement 

ATTACHMENT
3 - Development Plan 

ATTACHMENT
4 - Stock Purchase Agreement

ATTACHMENT
5 - Shareholder’s Agreement

ATTACHMENT
6 - Form NDA 

ATTACHMENT
7 - Client and Billing Agreement

ATTACHMENT
8 - Required Territories 

[
* ]

Page 26 of
26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]